



New Advances in Treatment of Sepsis

Guest Editor:

Dr. Yutaka Umemura

Division of Trauma and Surgical
Critical Care, Osaka General
Medical Center, Osaka, Japan

Deadline for manuscript
submissions:

closed (27 May 2022)

Message from the Guest Editor

Dear Colleagues,

Sepsis is now defined as an organ dysfunction caused by an overwhelming and life-threatening host response to infection. Excessive inflammatory response in sepsis subsequently leads to multiple organ dysfunction syndrome due to vascular endothelial dysfunction, coagulation disorders, alterations in cell function, and dysregulated cardiovascular responses. Despite the progress made in medical management over the past few decades, sepsis remains an important global health problem, with approximately 11 million sepsis-related deaths reported in 2017. Although various strategies to control sepsis-induced inflammation and organ dysfunction have been evaluated over the past several decades, there is still no proven therapeutic intervention benefitting survival. Therefore, updating knowledge on the pathophysiology of sepsis is a vitally important issue to construct a novel therapeutic strategy of sepsis. In this Special Issue of the *Journal of Personalized Medicine*, we will discuss the etiology, pathophysiology, clinical manifestations, diagnostic, and optimal management to treat critically ill patients with sepsis.

Dr. Yutaka Umemura

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)